Navigation Links
FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients

CINCINNATITransplant researchers at the University of Cincinnati (UC) have received a grant from the U.S. Food and Drug Administration to study the safety and efficacy of a generic immunosuppressive drug in high-risk transplant patients.

Rita Alloway, PharmD, UC research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, received a $2.25 million FDA grant to run two clinical trials studying the effects of immunosuppressant tacrolimus (Prograf and generics) in high-risk transplant patients.

Tacrolimus is a "cornerstone drug" in post-transplant immunosuppression, used after transplant to reduce the activity of the patient's immune system and lower the risk of rejection. Generic versions were introduced in 2009. Currently Alloway estimates more than 70 percent of transplant patients are dispensed generic tacrolimus.

"The largest concern for clinicians is the switchability between various generics," says Alloway. "When patients receive their prescription, they could be getting medication from different manufacturers each month. Most immunosuppressant drugs require individualized dosing and careful management to ensure the proper blood concentrations are maintainedtoo high exposure to these drugs increases the risk of toxicity, over-immunosuppression and cancer in patents. Too low exposure may lead to rejection of the organ by the patient's immune system."

The three-year grant will support retrospective and prospective studies in high-risk transplant recipients who have converted from branded tacrolimus to a generic version.

In the retrospective study, transplant recipients will be assessed one year prior and one year post conversion to the generic, with researchers assessing their tacrolimus dose changes, incidence of rejection, hospital admission, changes in renal function and changes in transplanted organ function.

The prospective study will compare the bioavailability and steady-state pharmacokinetics of six tacrolimus formulations in a six-way cross-over study. This study will compare patients who express the CYP3A5 enzyme and those who do not, as CYP3A5 expressors have been shown to require larger doses of tacrolimus to attain therapeutic blood concentrations.

Preliminary data from Alloway's tacrolimus research has suggested a link between CYP3A5 expression and peak tacrolimus levels after dosing in generic tacrolimus formulations.

"This study will analyze an enriched patient population based upon genetic factors which predispose the patient to be high risk and most likely to experience problems with generic switching if problems exist," states Alloway.

In 2012, Alloway received a $2.7 million grant from the FDA to study whether the two most disparate generic versions of tacrolimus are bioequivalent to the branded, or innovator, version of the drug in stable transplant patients.

"The results of these studies should address public concerns regarding the use of generic tacrolimus formulations in transplant recipients and provide the transplant clinician and recipients with objective data to address their concerns," she says.


Contact: Katy Cosse
University of Cincinnati Academic Health Center

Related medicine news :

1. T.E.N. Announces Winners of the ISE® North America Awards
2. The Global Awards World’s Best Healthcare Advertising Hosts Celebrations in New York City & Sydney, Australia
3. The Optical Society Presents Awards to Winners of Its Inaugural ‘Enabled by Optics’
4. Wells Fargo Supports Hospice Care as Diamond Sponsor of Pathways Hospice Awards Breakfast
5. Reviews "Face Fitness Formula" and Awards the Latest Guide Released by Face Fitness Center
6. Force Marketing Honored in Inc. Magazine Hire Power Awards for 2013
7. The Home Depot Foundation Awards Swords to Plowshares $24,000 to Renovate Housing for Veteran Families
8. Barton Publishing Honored as Silver Winner in 2013 Golden Bridge Awards “Best Customer Satisfaction Program of the Year”
9. National Robotics Initiative Awards provide $7 million for Carnegie Mellon research projects
10. American Eurocopter Awards Honor Leaders in Air Medical Safety
11. IPM receives 2 awards from USAID to advance HIV prevention technologies for women
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology: